During the August 31 episode of Mad Money, Jim Cramer addressed shifting market dynamics, highlighting how the fallout from heavily crowded hedge fund positions was finally unwinding. Turning his attention to a heavily shorted stock on Wall Street, Cramer pointed to Moderna, Inc. (NASDAQ:MRNA) and explained why skeptics were forced to rethink their thesis. He stated:
Now, I don’t want to say that Situational Awareness, again that’s the hedge fund, has disappeared. The fund still has some assets. Still, the fallout from its collapse does finally seem to be unwinding. Still, when you look at the 10 best and worst performers for the month, they’re stark in their themes that include the unwind of the Situational positions. Let’s go over the winners first. First, let’s start with a heavily shorted stock known as Moderna. Yes, there was a huge bet being made against these guys. Skeptics believed that its technology would never produce the breakthroughs that the bulls expected and were initially promised when the company came public. But this month, that’s exactly what we got. See, working with Merck, Moderna’s developed a vaccine for those who have beaten melanoma once. Now, this, my friends, is miraculous. So, it got a miraculous welcome. Do you know what? I think this could still have a huge potential to go higher.
Transforming Cancer Treatment with Merck
The basis of Moderna, Inc.’s (NASDAQ:MRNA) recent transition is its co-development partnership with Merck. Together, the companies advanced an mRNA-based personalized cancer vaccine designed to prevent melanoma recurrence in patients who have already beaten the disease once.
Beyond oncology, Moderna has worked to diversify its commercial footprint. Management has navigated a sharp post-pandemic revenue drop by tightening operational controls, tightening operating costs, and maintaining a solid cash cushion of $6.9 billion.
Cash Burn and Clinical Execution Risks
Despite the enthusiasm surrounding its cancer pipeline, Moderna, Inc. (NASDAQ:MRNA) remains a high-risk bet. The company continues to post substantial net losses, reporting a quarterly net loss of nearly $0.8 billion, along with heavy research expenditures needed to push its pipeline forward.
Furthermore, execution risks remain high across late-stage clinical programs. If subsequent trial milestones stumble or regulatory timelines face delays, valuation multiples built on future oncology success could face sharp downward pressure. Additionally, translating clinical breakthroughs into profitable commercial products requires sustained capital allocation.
Institutional Positioning and Short Interest
According to Insider Monkey’s Q2 data, institutional backing for Moderna, Inc. (NASDAQ:MRNA) contracted slightly, with 49 hedge funds holding stakes compared to 52 in the prior quarter. Short interest sits high at 16.16% of the public float, showing that plenty of skeptics remain willing to bet against the company.
Cramer highlighted a classic trap in market psychology. Writing off a pharmaceutical pioneer based entirely on fading pandemic revenues ignores how heavy research investments eventually translate into blockbuster commercial products. When a heavily shorted biotech stock delivers a genuine clinical breakthrough in oncology, traders banking purely on historical decay often get caught off guard, clearing the path for substantial upside as sentiment turns.
READ NEXT: Jim Cramer on Palantir (PLTR): “It’s a Great Spec, But It Is a Spec” and Jim Cramer Questions AEVEX (AVEX) Stock Sell-Off.
Disclosure: None. Follow Insider Monkey on Google News.
